The stock of Venaxis Inc (NASDAQ:APPY) is a huge mover today! About 276,467 shares traded hands or 1535.42% up from the average. Venaxis Inc (NASDAQ:APPY) has 0.00% since April 28, 2016 and is . It has underperformed by 5.93% the S&P500.
The move comes after 9 months positive chart setup for the $17.71M company. It was reported on Dec, 1 by Barchart.com. We have $4.10 PT which if reached, will make NASDAQ:APPY worth $1.42 million more.
Analysts await Venaxis Inc (NASDAQ:APPY) to report earnings on March, 22.
According to Zacks Investment Research, “Venaxis, Inc. is a biomedical diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test, APPY1. APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain. Venaxis, Inc., formerly known as AspenBio Pharma, Inc., is based in Castle Rock, Colorado.”
More notable recent Venaxis Inc (NASDAQ:APPY) news were published by: Prnewswire.com which released: “Venaxis Announces Acquisition of BiOptix” on September 13, 2016, also Quotes.Wsj.com with their article: “Venaxis Inc. APPY (US: Nasdaq)” published on February 11, 2011, Businesswire.com published: “INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced By Glancy …” on February 18, 2015. More interesting news about Venaxis Inc (NASDAQ:APPY) were released by: Prnewswire.com and their article: “AspenBio Pharma Changes Company Name to Venaxis, Inc.” published on December 12, 2012 as well as Seekingalpha.com‘s news article titled: “Why Numerous Upside Scenarios Make Venaxis A Biotech To Buy (APPY)” with publication date: April 21, 2015.
APPY Company Profile
Venaxis, Inc. (Venaxis), incorporated on July 24, 2000, is an in vitro diagnostic firm that is focused on commercializing its blood test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children, adolescent and young adults. The Company’s test, the APPY1 Test, is a blood test panel for aiding in identifying patients in the emergency department that are at low risk for acute appendicitis. The APPY1 System consists of a small fluorometer (APPYReader Instrument) and consumable test products (APPYReader QC Cassette, APPY1 Controls and APPY1 Test). The APPYReader Instrument measures fluorescence from the APPY1 Test cassette and the APPYReader QC Cassette, the APPYReader QC Cassette enables for functioning of the APPYReader Instrument, and the APPY1 Controls enable functioning of the APPY1 Test components. The APPY1 Test combines the concentrations of approximately three analytes, such as white blood cell count (WBC), C-reactive protein (CRP) and Venaxis’ myeloid-related protein 8/14 (MRP 8/14), using an algorithm to provide a result to the physician to aid in the identification of patients at low risk for acute appendicitis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.